Trial
NCT04154956
SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Sanofi
Collaborators
—
Condition
Non-small Cell Lung Cancer Metastatic
Intervention
SAR408701
Why stopped
Sponsor decision, the decision is not related to any safety concern.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-05-18